mCRPC 患者接受首次新型激素治疗后应用第二代新型激素治疗或镭-223 的真实世界结局。
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
机构信息
Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Departments of Medicine & Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
出版信息
Future Oncol. 2022 Jan;18(1):35-45. doi: 10.2217/fon-2021-0886. Epub 2021 Oct 12.
To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Retrospective analysis of the US Flatiron database (ClinicalTrials.gov identifier: NCT03896984). In the radium-223 cohort (n = 120) versus the alternative NHT cohort (n = 226), proportionally more patients had prior symptomatic skeletal events and bone-only metastases, and first-line NHT duration was shorter. Following second-line therapy, 49 versus 39% of patients received subsequent life-prolonging therapy; of these, 47 versus 76% received taxane. Median overall survival was 10.8 versus 11.2 months. Real-world patients with mCRPC had similar median overall survival following second-line radium-223 or alternative NHT after first-line NHT. Many patients received subsequent therapy, with less taxane use after radium-223.
评估镭-223 或其他新型激素治疗（NHT）在转移性去势抵抗性前列腺癌（mCRPC）一线 NHT 后的真实世界临床结局。对美国 Flatiron 数据库（ClinicalTrials.gov 标识符：NCT03896984）的回顾性分析。在镭-223 队列（n=120）与其他 NHT 队列（n=226）中，比例上更多的患者具有先前的症状性骨骼事件和仅骨转移，并且一线 NHT 持续时间较短。在二线治疗后，49%的患者与 39%的患者接受了后续的延长生命治疗；其中，47%的患者与 76%的患者接受了紫杉烷治疗。中位总生存期为 10.8 个月与 11.2 个月。在一线 NHT 后接受二线镭-223 或其他 NHT 的 mCRPC 真实世界患者的中位总生存期相似。许多患者接受了后续治疗，在接受镭-223 治疗后，紫杉烷的使用减少。
Zotero 插件